Archive | October, 2019

Announcing RESI Asia Innovation Challenge Finalists

31 Oct

By Karen Deyo, Senior Investor Research Analyst, LSN

We are excited to announce the finalists in the Innovation Challenge at both RESI Shanghai, taking place on Tuesday, Nov. 12th and RESI Taipei, taking place on Thursday, Nov. 14th. These companies will present posters in the Exhibit Hall, where RESI attendees can see their innovative technologies and ‘invest’ their ‘RESI cash’ tokens to vote for their favorite companies. The three companies with the most ‘invested’ by the end of the day will win prizes.

In addition to presenting posters, for the first time, each company will also get an opportunity to pitch to a panel of investors and industry experts, who will ask questions and provide feedback. Below are the pitching schedules for the selected companies – make sure to stop by and watch these amazing companies pitch!

RESI Shanghai Innovation & Pitch Challenge

RESI Taipei Innovation & Pitch Challenge

What is Partnering? – The Importance of Partnering in the Life Sciences

31 Oct

By Lucy Parkinson, VP of Investor Research, LSN

At LSN, we talk a lot about life science partnering meetings: our goal is to make RESI Partnering as productive for our RESI attendees as possible. LSN founded RESI because we had learned that while there are many other partnering events in the life science world, the experience was often lacking and we thought we could substantially improve it (and we have). Partnering is so instinctive for us that we rarely stop to think about what partnering is, and why it’s so important in the life science sector in particular: you might say partnering is just in our DNA.

As we’ve brought RESI to Asia, we’ve learned about how Asia has a different style of doing business conferences, where partnering is much less widely known. We therefore wanted to make a ground-up introduction to life science partnering.

Why Partnering, Why In Life Science?

Partnering was originally driven by the needs of big pharma companies. These firms have an intense focus on developing their future pipelines, and this often means looking for external assets that they could license in to bolster their strategies as existing products move toward the end of patent life. Pharmas draw up specific maps of the technologies that they need, and have sophisticated teams that look externally for these assets.

The life sciences industry is as much a people business as it is a technology business. When a pharma company licenses an asset, that often means embarking on years of co-development work in which the pharma and the startup share resources and expertise to bring the product through clinical trials. It’s therefore essential to meet people face to face, get to know how they work, and learn to trust them. However, networking in a conference hall isn’t the best way to find the people who are developing those specific technologies that are needed.

Partnering events offered pharma BD staff a way to meet lots of drug development entrepreneurs in one place, by using an online system to receive meeting requests and select in advance who they wanted to connect with at the event. This offered much more efficiency than networking, and a much more personal connection than watching a startup give a pitch on a stage.

Since its origin, partnering events have also served other investors and life science players as well, such as CROs and other service providers who can use the events to connect with new customers who need their particular expertise.

What happens at a partnering event?

When you register for a partnering event like RESI, you will be added to an online meeting schedule system that you can use to plan your day.  You can use this system to send messages to other attendees and ask them to meet with you.  You will also receive messages from other attendees, and can decide whether to accept or decline their meeting requests.  In this way, every attendee manages their own schedule and decides for themself who they would like to meet.

If a meeting request is accepted, the system will find a time and location for the meeting.  The locations will be numbered tables or booths where you can sit down and talk to your meeting partner, usually for 30 minutes. It’s therefore possible to have in-depth conversations about your business with lots of people in one day.

If you have other plans throughout the day, such as a presentation or panel session you wish to attend, the partnering system will allow you to mark yourself as unavailable for meetings at those times.  Be sure to set your availability before you make any meeting requests.

How did RESI change partnering?

While partnering is generally more efficient than networking, it is still often hard to find meeting partners who are a good fit for your business. For example, if you are an entrepreneur developing a new cell therapy product in the cardiovascular space, it might be difficult to identify investors who are interested in this type of technology. You might inadvertently send requests to people who aren’t a relevant fit, and receive a poor return on your efforts. From the investor or pharma point of view, it can be very challenging to receive many unsuitable meeting requests at an event, and time-consuming to filter through them for good fits.

The other big challenge for entrepreneurs attending a partnering event is simply finding real investors who are ready to allocate. At many events, active investors are thin on the ground, and you might end up meeting someone who claims to be an ‘investor’ but is really just a broker or investment banker.

RESI’s key insights are thus: in life science, there are buyers (typically investors, big pharma and other corporations that invest strategically such as medical device corporations), and there are sellers (scientist-entrepreneurs and early stage companies). Good partnering depends on both of these sides having fully developed profiles that can be filtered to look for relevant fits.

The second key insight is that it takes a dedicated team to find investors, vet investors, invite them to the event, and profile their requirements. LSN’s Investor Research team is dedicated to speaking with investors and pharma/strategic investors worldwide and learning what they are looking for. Most RESI events have a 1:1 ratio of startups to investors, thereby maximizing an entreprenur’s chance of getting investor meetings.

The third key insight is that the life sciences industry is an extremely granular business. Everyone has their own niche of expertise and technological savvy, from antibodies to robotics to medical AI. In addition to technology type, stage of product development is also an extremely significant variable. There are some investors who specialize in making investments in preclinical or prototype-stage companies; meanwhile, others prefer to only invest after the company’s product has proven its clinical safety and/or efficacy. It’s therefore not enough to simply bring investors to an event, or to offer startups a chance to send messages to them. LSN’s Investor Research team prepopulate investor profiles with information on what the investor is looking for and what their criteria are, in order to help startups identify the investors who are truly a fit for them.

So how does that affect entrepreneurs?  It means you are more likely to meet the right people. It means that when you sit down across from an investor, you already know you have a good fit – they’re interested in technologies like yours, and they have money to invest in people like you. For hundreds of RESI attendees, these initial meetings have eventually led to receiving an investment.

As we bring RESI Partnering to Asia for the first time, we hope to continue this success and make many more new connections happen.

Video: The Redefining Early Stage Investments (RESI) Conference

31 Oct

By Nono Hu, Director of Marketing, LSN

The Redefining Early Stage Investments (RESI) Conference presents many great opportunities for life science entrepreneurs looking for investors. RESI offers entrepreneurs the opportunity to engage in 1-on-1 meetings – up to 16 scheduled 1-on-1’s in a day and many additional ad-hoc meetings!

Life Science Nation (LSN) isn’t just RESI though. This video provides an overview of how RESI fits together with LSN’s two other services, the LSN Investor Platform and LSN Company Platform, and also with Boston Innovation Capital (BIC), a registered broker dealer who is a wholly owned subsidiary of LSN.

Come learn about how attending RESI and utilizing our other services can help you find the investors you’re looking for in the video below! Also, be sure to register for RESI Asia for a chance to experience how RESI can help you make the connections you need to get the investment you need.

Hot Investor Mandate: Venture Capital Firm Partners With Hospitals to Launch New Medical Technologies

31 Oct

A Venture Capital firm specializing in technologies, financials and healthcare industries has an investment management team that includes many experts and experienced professionals from hospitals and healthcare systems.  The firm has partnered with premier hospitals in the US, Taiwan and China to introduce new technologies.

The investment strategy of the firm has three main sectors: Greater China’s healthcare reform opportunities, disruptive medical technologies & business models, and synergies with their domestic and foreign hospital & medical network.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Global Technology Corporation Invests in Software-Enabled Devices

31 Oct

The healthcare and life sciences branch of a global technology corporation and manufacturing company looks to invest primarily in Series A or later companies in digital health, medical devices, genomics and molecular diagnostics technologies, but can expand their focus conditionally. While some of their investments are strategic to the parent company, the firm is willing to invest outside of corporate strategic areas. The firm is a global investor, and can act as both a strategic partner and a financial investor, depending on the company.

The firm can invest as a strategic manufacturing company, but is also interested in software-enabled technologies and connected devices. While the firm may consider PMA devices, most investments are in 510k-pathway products. For purely digital health products, such as IoT technology, the firm would like to see some revenue and market traction before investing. For both medical devices and digital health, the firm is agnostic to indication. Firm’s interest in genomics and molecular diagnostics primarily relate to the oncology space, and prefer to see technologies with some clinical data.

The firm may take a board seat after investing, if they are the lead or if they have strategic value to offer the portfolio company, but will generally not take a board seat if they are co-investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Japan Private Equity Looking Globally for Therapeutics, Devices and Digital Medicine

31 Oct

A private equity firm based in Japan makes venture stage investments, with  a typical investment size of USD 3-5 million per company. The firm’s geographical focus is Asia, centered on Japan and Taiwan. However, the firm may consider companies in the US and Europe. The firm is actively seeking new investment opportunities.

In the life sciences, the firm will primarily focus on therapeutics, and is also interested in medical devices and digital medicine. The firm is interested in new technologies such as cell and gene therapies, but also considers investing in small molecules and biologics, as well as biosimilars and reformulated drugs. The firm will invest in any indication area. The firm invests in companies from the late preclinical stage through to Phase II.

The firm is usually a follow-on investor. For early stage opportunities, the firm prefers that the company has a clinical trial plan in place. While the firm is interested in international opportunities, they prefer that the company is interested in expanding into Japan or Taiwan.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Angel Fund Makes Seed and Pre-A Round Investments

31 Oct

A biotech angel investment fund founded in 2016 and headquartered in Taiwan has a fund size of $50M and an average ticket size range from $250K to $1M. The fund mainly focuses on early-stage biotechnology and medical device companies and is looking to invest in seed to pre-A round.

The firm is looking for new investment opportunities across a wide spectrum of life science sectors. The current pipeline includes biotechnology platforms, medical devices, therapeutics and service platforms.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.